Finance

Grifols says on course to meet 2025 outlook as net profit triples

Published by Global Banking & Finance Review

Posted on May 12, 2025

1 min read

· Last updated: January 23, 2026

Add as preferred source on Google
Grifols says on course to meet 2025 outlook as net profit triples
Global Banking & Finance Awards 2026 — Call for Entries

(This story has been corrected to fix the spelling of the company name in the headline, and to add a dropped word 'to,' in paragraph 3) MADRID (Reuters) -Grifols's net profit almost tripled from a

Grifols Triples Net Profit, Confident in 2025 Targets

(This story has been corrected to fix the spelling of the company name in the headline, and to add a dropped word 'to,' in paragraph 3)

MADRID (Reuters) -Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.

Reported group profit grew by 179% in the first three months of the year to 60 million euros ($66.41 million) while adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) grew 14.2% to 400 million euros, Grifols said in a statement on Monday.

Net revenue rose 7.4% to 1.79 billion euros in the first quarter thanks to a strong performance from its plasma-derived medicine business.

($1 = 0.9035 euros)

(Reporting by Charlie Devereux; editing by Inti Landauro)

Key Takeaways

  • Grifols's net profit increased by 179% in Q1.
  • The company remains confident in its 2025 outlook.
  • Adjusted EBITDA grew by 14.2% to 400 million euros.
  • Net revenue rose 7.4% to 1.79 billion euros.
  • Strong performance in plasma-derived medicines.

Frequently Asked Questions

What is the main topic?
The article discusses Grifols's significant profit increase and its confidence in meeting its 2025 financial outlook.
How much did Grifols's net profit increase?
Grifols's net profit increased by 179% in the first quarter compared to the previous year.
What contributed to Grifols's revenue growth?
The revenue growth was driven by a strong performance in its plasma-derived medicine business.

Related Articles

More from Finance

Explore more articles in the Finance category